RXi Pharmaceuticals Corp. (NASDAQ:RXII) shares fell 2.9% during mid-day trading on Thursday . The stock traded as low as $2.33 and last traded at $2.33, with a volume of 50,745 shares. The stock had previously closed at $2.40.

Several brokerages have issued reports on RXII. Zacks Investment Research cut shares of RXi Pharmaceuticals Corp. from a “buy” rating to a “hold” rating in a report on Friday, July 15th. HC Wainwright began coverage on shares of RXi Pharmaceuticals Corp. in a report on Tuesday, June 7th. They set a “buy” rating and a $3.50 target price on the stock.

The firm’s 50 day moving average price is $2.37 and its 200-day moving average price is $2.48. The stock’s market cap is $15.28 million.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) last announced its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. During the same quarter last year, the firm posted ($0.50) EPS. On average, equities analysts predict that RXi Pharmaceuticals Corp. will post ($1.40) earnings per share for the current fiscal year.

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.